Research and Application for New Clinical Diagnosis and Treatment System for HBV Related HCC Liver Transplantation

Zhejiang University

Status: Completed

Conditions: Liver Transplantation; Hepatocellular Carcinoma; Prognosis

Treatments: Genetic: FKBP12 expression

Study type: Observational

Funder types: Other

Identifiers

NCT06409507

2018768

Details and patient eligibility

About

The study evaluated the protein expression levels of FK506-binding protein 12 (FKBP12) in hepatocellular carcinoma (HCC) and paracancerous tissues using immunohistochemistry (IHC). This study aimed to determine the role of FKBP12 in the outcome of liver transplantation recipients with HCC, especially those exceeding the Milan criteria. In addition, we explored how sirolimus administration affected LT recipients'prognosis depending on different FKBP12 expression, aiming to provide some advice for clinical sirolimus application after LT.

Enrollment: 178 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• (1) pathologically confirmed HCC (2) full post-LT follow-up record

Exclusion criteria

• (1)sirolimus treatment less than 30 days or after tumor recurrence (2)died within 90 days (3)underwent multiple-organ transplantation

Trial design

178 participants in 2 patient groups

high FKBP12 expression

Description:

The immunoreactive score (IRS), calculated by multiplying the staining intensity grades by the proportion of positive cells, was used to assess the expression levels of FKBP12. IRS (8-12) represented high expression levels.

Treatment:

Genetic: FKBP12 expression

low FKBP12 expression

Description:

The immunoreactive score (IRS), calculated by multiplying the staining intensity grades by the proportion of positive cells, was used to assess the expression levels of FKBP12. IRS (0-7) represented low expression levels.

Treatment:

Genetic: FKBP12 expression